In Brief: Quidel
This article was originally published in The Gray Sheet
Executive Summary
Quidel: Files 510(k) application with FDA for its QuickVue "one-step" Helicobacter pylori test. Designed for use with whole blood at point-of-care locations, the new product represents an advance over earlier versions of the test and would provide greater ease-of-use than competing products, the firm claims. Quidel also announces 510(k) clearance of its QuickVue Chlamydia test. Described as "a lateral flow immunoassay containing highly specific antibodies reactive to the Chlamydia organism," the test combines "fewer steps and faster results" and the "highest sensitivity among rapid tests" to allow physicians "to perform immediate, in-office detection and treatment," the firm says. Quidel submitted the premarket notification in January...
You may also be interested in...
EU Regulatory Assessors Get AI Boost In Reaching Scientific Decisions
The European Medicines Agency is training scientific staff working for the European medicines regulatory network in how to use a new AI-powered search engine that allows them to easily retrieve information on regulatory precedents.
EU Parliament Stricter Than Council On Medicines And Medical Devices Packaging
The EU Parliament's Environment, Public Health and Food Safety committee takes a compromise position with regards to the Packaging and Packaging Waste Directive. Medicines and medical devices should be exempt, but only until 2035, at which point the European Commission should check whether the development of materials and the recycling process have progressed, and may adjust this exemption accordingly.
Stay Or Exit? Global Health Players Ponder New China Trajectory
It's again the time of year when global CEOs descend on China's capital to discuss strategies. This year, however, the mood is different.